Clinical Trial Article Title

**Abstract**:

Around 250-350 words, a structured abstract is required by summarizing the research components. Write 1-3 sentences for each of the following headings to form your Structured abstract: **Introduction, Methods,** **Results, Discussion (Optional), Conclusion.**

Citations, References, Hyperlinks and Abbreviations should not appear in the abstract. Use this abstract in the System Abstract box.

**Introduction**:

This is the literature review and background of your research. Most of your citations should appear here. The references used should be as current as possible. Avoid making your introduction as a textbook. Aims and Objectives should be in the methods component.

**Methods**:

Write a clear methodology stating trial design, eligibility criteria for participants, data collection, intervention and comparison. The Methods section should include a statement indicating if the research was approved by an independent local, regional or national review body (don’t write the organization name). The Clinical Trial should be assessed based on the guidelines Consolidated Standards of Reporting Trials [CONSORT](http://www.consort-statement.org/). All information and/or data obtained during the study should be added in the Results section.

**Results**:

In this section, without interpretation or bias, describe and tabulate your trial findings results based on the methodology you designed. The results section should state the findings of the research arranged in a logical sequence without interpretation.

Tables and/or figures should be uploaded as separate files and not embedded in the main text.

**Discussion**:

In this section, interpret and evaluate your results and benchmark with previous similar literature. Limitations of the study might be mentioned in your Conclusion. Little citation should appear here.

**Conclusion**:

In this section, make a short clear conclusion and recommendation supported by evidence from your results. The recommendation should be for global science and not limited to your organization. Don’t use a previously published paper conclusion in this section. No citations should appear in this section.

**Statements (2)**:

**Ethical Statement**: Authors should show that studies involving Human Participants were planned, conducted and reported in accordance with The World Medical Association (WMA) [Declaration of Helsinki](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Studies involving Animals should be conducted in accordance with the guidelines of the Animal Research: Reporting of *In Vivo* Experiments ([ARRIVE](https://arriveguidelines.org/arrive-guidelines)).

Clinical Trials should conform to the [ICMJE](http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html) requirement that clinical trials are registered in a [WHO](https://www.who.int/clinical-trials-registry-platform/network) approved public trials registry at or before starting the trial and the clinical trial number must be clearly stated here.

**Ethical Approval**: To ensure ethical research practices, authors must obtain prior approval from an independent ethics committee, such as a local Institutional Review Board (IRB) or a national ethics committee. Please state clearly (Committee Name, Approval number and Date). The editors reserve the right to request the ethical approval copy for verification.

Studies involving Animals, Authors should seek prior approval from an Institutional Animal Care Committee or equivalent ethics committee. Full Committee name, Decision number and Date are required.

In both cases for Human or Animal studies, if the ethical approval exempted, Authors to state clearly the Committee name exempted the ethical approval, Decision number and Date.

**Informed Consent Statement**: Authors to state that Written Informed Consent was obtained from all participants to participate in the study. If waived, the reason, the name of the committee, the guideline and/or the policy should be clearly stated.

**Artificial Intelligence (AI) Disclosure Statement**: On submission, the author(s) to disclose whether they used Artificial Intelligence (AI) in the production of submitted work. If AI is used, please use this suggested Statement: “During the preparation of this study the author(s) used [TOOL Name/ SERVICE Name] in writing assistance, data collection, analysis and/or figure generation. After using this AI tool/service, the author(s) revised and edited the content and take(s) full responsibility for the publication”. If not applicable, write “AI-Unassisted Work”.

**Data Sharing Statement**: pre- and/or post-publication, Authors are required to publicly make their research data set available. If not, Authors to specify the reasons and alternatives to access the data. Select from below your appropriate statement:

-Date sets are available publicly in the depository storage at https://(website).

-Date sets are Not available publicly because of legal/security/privacy/policy reasons. However, it’s available by request from the Correspondence Author.

-All Data sets are included in the published article.

**References**:

Use Vancouver style. In-text citation: each reference is assigned a number between brackets (1) based on its placement in your paper. Create your Reference list from the citations you used as they appear in your paper and arrange them numerically using Arabic numerals.

**Figure Legends**: